Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.23.2
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 15 Months Ended 27 Months Ended
Jul. 01, 2021
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Sep. 30, 2022
Dec. 31, 2024
Disaggregation of Revenue [Line Items]              
Total revenue   $ 643 $ 1,033 $ 1,117 $ 2,206    
Allowance for other long-term asset       0 1,000    
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio              
Disaggregation of Revenue [Line Items]              
Proceeds from divestiture of businesses           $ 2,000  
Total receivable balance   1,000   1,000      
Allowance for other long-term asset     1,000        
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Forecast              
Disaggregation of Revenue [Line Items]              
Proceeds from divestiture of businesses             $ 1,000
Product revenue, net              
Disaggregation of Revenue [Line Items]              
Total revenue   $ 643 $ 1,033 $ 1,117 $ 2,206    
Millipred | Teva              
Disaggregation of Revenue [Line Items]              
Percent of net profit for installment payments           50.00%  
Installment payment $ 500            
Major Customer Number One | Sales Revenue | Customer Concentration Risk              
Disaggregation of Revenue [Line Items]              
Concentration risk percentage   65.00%   63.00%      
Major Customer Number Two | Sales Revenue | Customer Concentration Risk              
Disaggregation of Revenue [Line Items]              
Concentration risk percentage   35.00%   37.00%